NEW YORK, April 1 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
AstraZeneca plc: PharmaVitae Profile
http://www.reportlinker.com/p0185092/AstraZeneca-plc-PharmaVitae-Profile.html
Introduction
This analysis examines the historical and forecast performance for AstraZeneca in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
*Benchmark AstraZeneca's performance against key rivals in the prescription pharmaceutical sector
*Assess the commercial impact of AstraZeneca's recent movement into the biologics market, spearheaded by its acquisition of MedImmune
*Analyse the exposure of AstraZeneca's blockbuster portfolio to patent expiration and generic competition through to 2015
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly update 3
Company introduction 3
Company sales 4
Company financials 4
Key products 4
Data sourcing 4
Sales data 4
Analyst consensus 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2003-15 6
Financial performance, 2002-14 7
Note regarding full year 2009 financial data 7
AstraZeneca: PharmaVitae forecasts at a glance 8
Strategic insight 9
Highest material exposure to patent cliff in Big Pharma 9
Purity of blockbuster growth strategy facilitates high level of generic exposure 9
Overly dependent on small molecules 10
Exposed to cross-class therapeutic substitution 11
AstraZeneca cannot afford any more pipeline setbacks 11
MedImmune acquisition drives long term diversification into biologics and vaccines 14
Cost control essential to retain hope of profit growth 15
SWOT analysis 17
Strengths 18
Crestor franchise 18
Strong track record in cost control 18
Weaknesses 19
Over dependent on small molecules 19
Exposed to cross-class generic substitution 19
Recent history of pipeline failures 20
Over dependent on Crestor to drive 'Core' growth 20
Opportunities 20
Diversification into biologics and vaccines via MedImmune 20
Cost restructuring strategy 21
Potential blockbusters in late stage pipeline 21
Collaborations to boost near-medium term sales forecasts 22
Threats 23
Very high exposure to generic competition 23
No margin for failure in late stage R&D pipeline 23
Lack of strategic manoeuvrability stemming from MedImmune acquisition 23
Crestor patent case 23
TABLE OF CONTENTS 25
Table of figures 27
Chapter 3 Quarterly update 28
Latest comment 29
Q3 2009 29
AstraZeneca and Boehringer Ingelheim steal limelight at European Society of Cardiology meeting 29
Q2 2009 30
Merck and AstraZeneca: rivals join forces in oncology 30
Q1 2009 31
MAP Pharmaceuticals/AstraZeneca: setback for budesonide 31
AstraZeneca: nasal flu vaccine submitted for European approval 31
Latest prescription pharma product news 32
Q4 2009 32
Q3 2009 34
Q2 2009 36
Q1 2009 38
Latest corporate news 39
Q4 2009 39
Q3 2009 39
Q2 2009 39
Q1 2009 39
Future product milestones 40
Chapter 4 Company introduction 41
Key findings 41
Background 42
M&A history 42
Astra AB and Zeneca Group plc 42
Subsequent M&A activity 43
Abgenix 43
Cambridge Antibody Technology (CAT) 43
KuDOS Pharmaceuticals 43
Arrow Therapeutics 44
MedImmune 44
Albireo 44
M&A strategy 44
Chapter 5 Company sales 46
Key findings 46
Prescription pharmaceutical sales and growth rate analysis, 2003-15 47
Product analysis 48
Product analysis, 2003-09 50
Product analysis, 2009-15 52
Therapy area analysis 54
Geographic analysis 57
Launch/core/expiry analysis 59
Explanation of launch/core/expiry analysis 59
Launch analysis, 2009-15 60
Core analysis, 2009-15 61
Expiry analysis, 2009-15 62
Launch/core/expiry configuration, 2009-15 63
Molecule type analysis 64
Externalization analysis 66
Chapter 6 Company financials 68
Key findings 68
Note regarding full year 2009 financial data 69
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 69
Operating costs and profit analysis 70
Operating costs and profit analysis, 2002-08 71
Operating cost ratio and profit margin analysis, 2002-08 72
Operating cost ratio and profit margin analysis, 2008-14 73
Operating costs and profit analysis, 2008-14 74
Chapter 7 Key products 76
Overview 76
Crestor 77
Summary 78
Sales forecast 78
Brilinta 79
Summary 80
Sales forecast 80
Onglyza 81
Summary 81
Sales forecast 82
Certriad 82
Summary 83
Sales forecast 83
Dapagliflozin 84
Summary 84
Sales forecast 85
Seroquel 86
Summary 86
Sales forecast 87
Nexium 87
Summary 88
Sales forecast 88
Seloken/Toprol XL 89
Summary 89
Sales forecast 90
Pulmicort 90
Summary 91
Sales forecast 91
Arimidex 92
Summary 92
Sales forecast 93
Chapter 8 Appendix 94
References 94
Abbreviations 94
Exchange rates 95
About Datamonitor 96
About Datamonitor Healthcare 96
Datamonitor consulting 96
Disclaimer 98
LIST OF TABLES
Table 1: AstraZeneca - PharmaVitae forecasts at a glance 8
Table 2: AstraZeneca quarterly sales, Q408-Q409 28
Table 3: AstraZeneca future product milestones, 2010-12 40
Table 4: AstraZeneca product portfolio overview ($m), 2003-09 50
Table 5: AstraZeneca product portfolio overview ($m), 2009-15 52
Table 6: AstraZeneca prescription pharmaceutical sales by therapy area ($m), 2009-15 56
Table 7: AstraZeneca prescription pharmaceutical sales by geographic region ($m), 2009-15 58
Table 8: AstraZeneca launch portfolio overview ($m), 2009-15 60
Table 9: AstraZeneca core portfolio overview ($m), 2009-15 61
Table 10: AstraZeneca expiry portfolio overview ($m), 2009-15 62
Table 11: AstraZeneca prescription pharmaceutical sales by molecule type ($m), 2009-15 65
Table 12: AstraZeneca prescription pharmaceutical sales by source ($m), 2009-15 67
Table 13: Total AstraZeneca sales by business unit ($m), 2002-08 69
Table 14: AstraZeneca operating revenue/cost analysis ($m), 2002-08 71
Table 15: AstraZeneca operating cost ratio analysis (% of total revenues), 2002-08 72
Table 16: AstraZeneca operating cost ratio analysis (% of total revenues), 2008-14 73
Table 17: AstraZeneca operating revenue/cost analysis ($m), 2008-14 74
Table 18: AstraZeneca Key products overview 76
Table 19: Crestor: overview 78
Table 20: Crestor: sales forecast ($m), 2009-15 78
Table 21: Brilinta: overview 80
Table 22: Brilinta: sales forecast ($m), 2009-15 80
Table 23: Onglyza: overview 81
Table 24: Onglyza: sales forecast ($m), 2009-15 82
Table 25: Certriad: overview 83
Table 26: Certriad: sales forecast ($m), 2009-15 83
Table 27: Dapagliflozin: overview 84
Table 28: Dapagliflozin: sales forecast ($m), 2009-15 85
Table 29: Seroquel: overview 86
Table 30: Seroquel: sales forecast ($m), 2009-15 87
Table 31: Nexium: overview 88
Table 32: Nexium: sales forecast ($m), 2009-15 88
Table 33: Seloken/Toprol XL: overview 89
Table 34: Seloken/Toprol XL: sales forecast ($m), 2009-15 90
Table 35: Pulmicort: overview 91
Table 36: Pulmicort: sales forecast ($m), 2009-15 91
Table 37: Arimidex: overview 92
Table 38: Arimidex: sales forecast ($m), 2009-15 93
Table 39: Exchange rates, 2010 95
LIST OF FIGURES
Figure 1: The PharmaVitae Explorer 3
Figure 2: AstraZeneca prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15 6
Figure 3: AstraZeneca's financial performance ($m), 2002-14 7
Figure 4: AstraZeneca prescription pharmaceutical sales by Launch/Core/Expiry classification ($m), 2009-15 9
Figure 5: AstraZeneca prescription pharmaceutical sales growth by portfolio component (blockbusters, rest of portfolio, new launches) ($m), 2003-15 10
Figure 6: AstraZeneca 2009 prescription pharmaceutical sales by global launch period ($m) 12
Figure 7: AstraZeneca operating revenue/cost analysis ($m), 2002-14 16
Figure 8: AstraZeneca SWOT analysis 17
Figure 9: AstraZeneca prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15 47
Figure 10: AstraZeneca Key product sales ($m), 2003-15 48
Figure 11: AstraZeneca key sales growth drivers and resistors ($m), 2003-09 51
Figure 12: AstraZeneca key sales growth drivers and resistors ($m), 2009-15 53
Figure 13: AstraZeneca prescription pharmaceutical sales by therapy area ($m), 2003-15 54
Figure 14: AstraZeneca prescription pharmaceutical sales by geographic region ($m), 2003-15 57
Figure 15: AstraZeneca launch/core/expiry configuration ($m), 2009-15 63
Figure 16: AstraZeneca prescription pharmaceutical sales by molecule type ($m), 2003-15 64
Figure 17: AstraZeneca prescription pharmaceutical sales by source ($m), 2003-15 66
Figure 18: AstraZeneca operating revenue/cost analysis ($m), 2002-14 70
To order this report:
Pharmaceutical Industry: AstraZeneca plc: PharmaVitae Profile
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article